Meeting
2023 ASCO Annual Meeting
Efficacy of ovarian function suppression of 3-monthly versus monthly GnRH agonist as endocrine therapy for premenopausal breast cancer patients.
Authors
Daniella Audi Blotta
Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil
Daniella Audi Blotta , Jessica Ribeiro Gomes , Shermann Brandão Rodrigues Moreira , Danielle Fortes Colosimo , Carolina Cavalcanti Gonçalves Ferreira , Elaine Aparecida Forgiarini , Debora De Melo Gagliato , Antonio C. Buzaid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 527)
DOI
10.1200/JCO.2023.41.16_suppl.527
Abstract #
527
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch
Poster
2022 ASCO Annual Meeting
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).
First Author: Ryan Tooker
Poster
2023 ASCO Annual Meeting
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
First Author: Matthew P. Goetz
Poster
2023 ASCO Annual Meeting
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
First Author: Coralea Kappel